The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor

Cancer Immunology Research

Volumn 2, Issue 8, 2014, Pages 765-776

  Swierczak, Agnieszka ^a,b   Cook, Andrew D ^b   Lenzo, Jason C ^b   Restall, Christina M ^a   Doherty, Judy P ^a   Anderson, Robin L ^a,b   Hamilton, John A ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5-(3-METHOXY-4-((4-METHOXYBENZYL)OXY)BENZYL)PYRIMIDINE-2,4-DIAMINE; ANISOLE DERIVATIVE; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; PYRIMIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; IMMUNOLOGY; LEUKOCYTE COUNT; LUNG TUMOR; MONOCYTE; NEUTROPHIL; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; SPINAL CORD TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANISOLES; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; FEMALE; LEUKOCYTE COUNT; LUNG NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MAMMARY NEOPLASMS, ANIMAL; MICE, INBRED BALB C; MONOCYTES; NEUTROPHILS; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SPINAL NEOPLASMS; TUMOR BURDEN;

EID: 84918813152     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0190     Document Type: Article

References (61)

1. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66:1-9.
2. Pollard JW Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71-8.
3. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004; 14:628-38.
4. Byrne PV, Guilbert LJ, Stanley ER. Distribution of cells bearing receptors foracolony-stimulating factor (CSF-1)inmurine tissues. J Cell Biol 1981; 91:848-53.
5. Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 2012; 13:753-60.
6. Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol 2010; 88:495-505.
7. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994; 86:120-6.
8. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem 1992; 50:350-6.
9. Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, et al. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 1998; 4: 1851-6.
10. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004; 10:173-7.
11. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009; 15:778-87.
12. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
13. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193:727-40.
14. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004; 64:5378-84.
15. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S. Colonystimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006; 66: 4349-56.
16. ImClone LLC. Study of IMC-CS4 in subjects with advanced solid tumors; 2011 [cited 2014 May 5]. Available from: http://clinicaltrials.gov/show/NCT01346358.
17. Plexxikon. Safety study of PLX108-01 in patients with solid tumors; 2009 [cited 2014 May 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT01004861?term=PLX3397+and+cancer&rank=4.
18. Rugo H. Komen, Plexxikon, Eisai Inc. Phase Ib/II study of PLX 3397 and eribulin in patients with metastatic breast cancer; 2012 [cited 2014 May 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT01596751?term=PLX3397+and+cancer&rank=1.
19. + myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010; 70: 6139-49.
20. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89.
21. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 1993; 151:2399-408.
22. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211:609-18.
23. Chan J, Leenen PJ, Bertoncello I, Nishikawa SI, Hamilton JA. Macrophage lineage cells in inflammation: characterization by colony-stimulating factor-1 (CSF-1) receptor (c-Fms), ER-MP58, and ER-MP20 (Ly-6C) expression. Blood 1998; 92:1423-31.
24. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-61.
25. + granulocytes. Proc Natl Acad Sci U S A 2010; 107:21248-55.
26. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell 2009; 16:173-4.
27. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998; 152:83-92.
28. Zhao JJ, Pan K, Wang W, Chen JG, Wu YH, Lv L, et al. The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS ONE 2012; 7:e33655.
29. Yamashita J, Ogawa M, Shirakusa T. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J Leukoc Biol 1995; 57:375-8.
30. Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013; 34:81-9.
31. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999; 17:163-70.
32. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405.
33. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005; 3:1-13.
34. Rockwell S, Kallman RF. Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res 1973; 53: 281-94.
35. Lenzo JC, Turner AL, Cook AD, Vlahos R, Anderson GP, Reynolds EC, et al. Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol Cell Biol 2012; 90:429-40.
36. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461-71.
37. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A 2005; 102:16078-83.
38. Burns CJ, Harte MF, Bu X, Fantino E, Giarrusso M, Joffe M, et al. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS. Bioorg Med Chem Lett 2009; 19:1206-9.
39. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123:725-31.
40. Madden SF, Clarke C, Aherne ST, Gaule P, O'Donovan N, Crown J, et al. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 2013; 15:R52.
41. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012; 109:2796-801.
42. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 1999; 28:29-41.
43. Rose S, Misharin A, Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A 2012; 81:343-50.
44. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5.
45. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67.
46. Li R, Doherty J, Antonipillai J, Chen S, Devlin M, Visser K, et al. LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice. Clin Exp Metastasis 2013; 30:483-95.
47. Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, Stanley ER. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 1982; 28:71-81.
48. Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A 1987; 84:6179-83.
49. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008; 320:807-11.
50. Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 1991; 77:2154-9.
51. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. MCSF inhibition selectively targets pathological angiogenesis and lym-phangiogenesis. J Exp Med 2009; 206:1089-102.
52. Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS ONE 2013; 8:e73310.
53. Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011; 20:300-14.
54. Guleria I, Pollard JW. Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor 1-deficient mice. Infect Immun 2001; 69:1795-807.
55. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008; 10:329-40.
56. Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, et al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity 2012; 37:1050-60.
57. Goodale D, Phay C, Brown W, Gray-Statchuk L, Furlong P, Lock M, et al. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry B Clin Cytom 2009; 76:107-17.
58. Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol 2014; 46:138-47.
59. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72.
60. Silva MT Macrophage phagocytosis of neutrophils at inflammatory/ infectious foci: a cooperative mechanism in the control of infection and infectious inflammation. J Leukoc Biol 2011; 89:675-83.
61. Aharinejad S, Salama M, Paulus P, Zins K, Berger A, Singer CF. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer 2013; 20: 777-83.